Analysis offers new hope for failed fragile X drug

Editorial illustration for about Mavoglurant, an experimental drug for fragile X syndrome. Eye tracking shows that the drug enters the brain and boosts social interest allowing patients to have eye contact with people, task that’s always been difficult for those affected by this syndrome.